CSIMarket Company Name, Ticker, Suppliers, else..




 

Ethereum: 2,524.14 -48.3 -1.88% Bitcoin: 105,527.98 1,753.78 1.69% Monero: 343.51 8.4 2.52%


Ethereum: 2,524.14 -48.3 -1.88%


Bitcoin: 105,527.98 1,753.78 1.69%


Monero: 343.51 8.4 2.52%



  News about Stock Market Trading

Green Lights Shine on Wall Street as Healthcare and Services Stocks Propel Market Gains



On Friday, May 16, 2025, U.S.
stock markets opened strong, with major indices registering gains driven by robust performances in the healthcare and services sectors.
The day reflected broad-based optimism on Wall Street, particularly following a solid trading session the day prior.

The SandP 500, climbing for a potential fifth consecutive day, was buoyed by healthcare stocks, which rose by 0.87%, and the services sector, gaining 0.83%. Encouraging signs of market stability were reflected across the board, as major indices maintained their upward trajectories amid positive economic reports.

In specific stocks, Occidental Petroleum Corporation showcased impressive revenue growth and announced a strategic partnersh...



Click Here to see Shares currently trading at 52 week high




    Nasd100: 21,447 19.12 0.09%



Today's Stock Performance by Sector and Industry


Best Performing Sectors in the Year 2024 Best Performing Sectors in the Year 2023 Best Performing Sectors in the Year 2022
     
 
Best Performing Sectors
Utilities  0.50 %
Healthcare  0.43 %
Retail  0.42 %
Conglomerates  0.40 %
Financial  0.20 %
Basic Materials  0.19 %
  
     
     
 
Worst Performing Sectors
Energy -0.93 %
Technology -0.47 %
Capital Goods -0.29 %
Consumer Non Cyclical -0.27 %
Transportation -0.18 %
Consumer Discretionary -0.15 %
  
     
 
 1 Day   Week  Current Month of May  30 Days  Current Quarter Q2 of 2025  90 Days    Ytd    12 Months 
     
 
Best Performing Industries
Biotechnology & Pharmaceuticals  1.76 %
Accident & Health Insurance  1.63 %
Metal Mining  1.40 %
Automotive Aftermarket  1.24 %
Electric & Wiring Equipment  1.11 %
Tobacco  1.11 %
  
     


 
     
 
Worst Performing Industries
Legal Cannabis -8.10 %
Oil Well Services & Equipment -2.24 %
Publishing & Information -2.04 %
Department & Discount Retail -1.86 %
Oil & Gas Integrated Operations -1.36 %
Semiconductors -1.31 %
  
     

Today's Stock Performance by Sector and Industry


Best Performing Sectors
Utilities  0.50 %
Healthcare  0.43 %
Retail  0.42 %
Conglomerates  0.40 %
Financial  0.20 %
Basic Materials  0.19 %




Worst Performing Sectors
Energy -0.93 %
Technology -0.47 %
Capital Goods -0.29 %
Consumer Non Cyclical -0.27 %
Transportation -0.18 %
Consumer Discretionary -0.15 %


Best Performing Industries
Biotechnology & Pharmaceuticals  1.76 %
Accident & Health Insurance  1.63 %
Metal Mining  1.40 %
Automotive Aftermarket  1.24 %
Electric & Wiring Equipment  1.11 %
Tobacco  1.11 %




Worst Performing Industries
Legal Cannabis -8.10 %
Oil Well Services & Equipment -2.24 %
Publishing & Information -2.04 %
Department & Discount Retail -1.86 %
Oil & Gas Integrated Operations -1.36 %
Semiconductors -1.31 %


 



 

Best Performing Stocks From The Best Performing (Biotechnology & Pharmaceuticals) Industry Today





ARMP

$2.37

$1.0200 75.56%
Today's


ARMP

$2.37

$1.0200 75.56%



Armata Pharmaceuticals Inc

Armata Pharmaceuticals Inc shares increased 75.56% today.


Armata Pharmaceuticals Inc operates on a research and development business model focused on discovering and developing bacteriophage-based therapies to combat antibiotic-resistant infections. They utilize their proprietary phage technology platform to create novel pharmaceutical products targeting various bacterial diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 140.964 mill. $ - mill. $ -0.426 mill. 59 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 140.964 mill.
$ - mill.


$ -0.426 mill.
Employees Shares Outstanding P/E

8
59 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ELEV

$0.34

$0.0575 20.35%
Today's


ELEV

$0.34

$0.0575 20.35%



Elevation Oncology inc

Elevation Oncology Inc shares improved 20.35% today.


Elevation Oncology Inc*s business model focuses on precision medicine and targeted therapies for rare and genomically defined cancers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 20.119 mill. $ - mill. $ -47.989 mill. 59 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 20.119 mill.
$ - mill.


$ -47.989 mill.
Employees Shares Outstanding P/E

84
59 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


TIL

$16.9

$2.2700 15.52%
Today's


TIL

$16.9

$2.2700 15.52%



Instil Bio Inc

Instil Bio Inc stock increased 15.52% today.


Instil Bio Inc operates with a business model focusing on developing and commercializing innovative cell therapy products for the treatment of cancer. They aim to leverage advanced technologies and strategic partnerships to advance their pipeline and bring novel therapies to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 110.402 mill. $ 6.509 mill. $ -78.033 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 110.402 mill.
$ 6.509 mill.


$ -78.033 mill.
Employees Shares Outstanding P/E

65
7 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


NVAX

$7.74

$1.0100 15.01%
Today's


NVAX

$7.74

$1.0100 15.01%



Novavax inc

Novavax Inc shares went up 15.01% today.


Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,374.818 mill. $ 1,254.962 mill. $ 478.697 mill. 178 mill. 2.81 Y/Y 610.30 %
Market Cap. Revenues TTM Net Income TTM

$ 1,374.818 mill.
$ 1,254.962 mill.


$ 478.697 mill.
Employees Shares Outstanding P/E

370
178 mill.
2.81
Revenue Growth Income Growth

MRQ Y/Y 610.30 %
MRQ Y/Y - %


FATE

$1.22

$0.1500 14.02%
Today's


FATE

$1.22

$0.1500 14.02%



Fate Therapeutics Inc

Fate Therapeutics Inc shares improved 14.02% today.


Fate Therapeutics Inc*s business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 144.418 mill. $ 13.335 mill. $ -175.879 mill. 118 mill. - Y/Y -15.38 %
Market Cap. Revenues TTM Net Income TTM

$ 144.418 mill.
$ 13.335 mill.


$ -175.879 mill.
Employees Shares Outstanding P/E

220
118 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -15.38 %
MRQ Y/Y - %


ENGN

$3.91

$0.4600 13.33%
Today's


ENGN

$3.91

$0.4600 13.33%



Engene Holdings Inc

Engene Holdings Inc stock improved 13.33% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 199.320 mill. $ - mill. $ 69.047 mill. 51 mill. 2.64 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 199.320 mill.
$ - mill.


$ 69.047 mill.
Employees Shares Outstanding P/E

-
51 mill.
2.64
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y 129.82 %


SRZN

$8.03

$0.9300 13.10%
Today's


SRZN

$8.03

$0.9300 13.10%



Surrozen Inc

Surrozen Inc stock went up 13.10% today.


Surrozen Inc*s business model revolves around biotechnology and therapeutics, specifically focusing on regenerative medicine.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 29.133 mill. $ 11.638 mill. $ -81.704 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 29.133 mill.
$ 11.638 mill.


$ -81.704 mill.
Employees Shares Outstanding P/E

40
4 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


CRBU

$1.05

$0.1116 11.89%
Today's


CRBU

$1.05

$0.1116 11.89%



Caribou Biosciences Inc

Caribou Biosciences Inc shares improved 11.89% today.


Caribou Biosciences Inc is a biotechnology company that focuses on the development of gene editing technologies. Their business model involves licensing their proprietary CRISPR-Cas9 platform and collaborating with partners to advance research and therapeutic applications in various industries.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 97.313 mill. $ 9.918 mill. $ -147.862 mill. 93 mill. - Y/Y -3.13 %
Market Cap. Revenues TTM Net Income TTM

$ 97.313 mill.
$ 9.918 mill.


$ -147.862 mill.
Employees Shares Outstanding P/E

147
93 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -3.13 %
MRQ Y/Y - %


FENC

$7.65

$0.8100 11.84%
Today's


FENC

$7.65

$0.8100 11.84%



Fennec Pharmaceuticals inc

Fennec Pharmaceuticals Inc stock went up 11.84% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 166.770 mill. $ - mill. $ 1.549 mill. 22 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 166.770 mill.
$ - mill.


$ 1.549 mill.
Employees Shares Outstanding P/E

34
22 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


QNCX

$0.9493

$0.0993 11.68%
Today's


QNCX

$0.9493

$0.0993 11.68%



Quince Therapeutics Inc

Quince Therapeutics Inc shares went up 11.68% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 41.713 mill. $ - mill. $ -15.086 mill. 44 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 41.713 mill.
$ - mill.


$ -15.086 mill.
Employees Shares Outstanding P/E

36
44 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


CCCC

$1.54

$0.1600 11.59%
Today's


CCCC

$1.54

$0.1600 11.59%



C4 Therapeutics Inc

C4 Therapeutics Inc stock increased 11.59% today.


C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid? platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body*s natural protein degradation machinery.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 109.083 mill. $ 39.783 mill. $ -103.277 mill. 71 mill. - Y/Y 138.17 %
Market Cap. Revenues TTM Net Income TTM

$ 109.083 mill.
$ 39.783 mill.


$ -103.277 mill.
Employees Shares Outstanding P/E

110
71 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 138.17 %
MRQ Y/Y - %


TECX

$23.41

$2.4200 11.53%
Today's


TECX

$23.41

$2.4200 11.53%



Tectonic Therapeutic Inc

Tectonic Therapeutic Inc stock increased 11.53% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 401.661 mill. $ - mill. $ -67.080 mill. 17 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 401.661 mill.
$ - mill.


$ -67.080 mill.
Employees Shares Outstanding P/E

77
17 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


SCLX

$4.695

$0.4850 11.52%
Today's


SCLX

$4.695

$0.4850 11.52%



Scilex Holding Company

Scilex Holding Company stock went up 11.52% today.


Scilex Holding Company operates as a pharmaceutical company focused on the development and commercialization of prescription drugs. Through its business model, it aims to identify and acquire assets that have the potential to address unmet medical needs and improve patient outcomes. The company primarily focuses on developing innovative, differentiated products in the therapeutic areas of pain management and neurology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 54.298 mill. $ 50.710 mill. $ -74.510 mill. 12 mill. - Y/Y -54.02 %
Market Cap. Revenues TTM Net Income TTM

$ 54.298 mill.
$ 50.710 mill.


$ -74.510 mill.
Employees Shares Outstanding P/E

115
12 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -54.02 %
MRQ Y/Y - %


AUTL

$1.48

$0.1500 11.28%
Today's


AUTL

$1.48

$0.1500 11.28%



Autolus Therapeutics Plc

Autolus Therapeutics Plc stock increased 11.28% today.


Autolus Therapeutics Plc is a biopharmaceutical company that focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Their business model is centered around utilizing innovative technology and expertise to create and advance novel therapies aimed at improving patient outcomes in oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 393.867 mill. $ 9.011 mill. $ -238.133 mill. 266 mill. - Y/Y -10.99 %
Market Cap. Revenues TTM Net Income TTM

$ 393.867 mill.
$ 9.011 mill.


$ -238.133 mill.
Employees Shares Outstanding P/E

201
266 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -10.99 %
MRQ Y/Y - %


FDMT

$3.8

$0.3600 10.47%
Today's


FDMT

$3.8

$0.3600 10.47%



4d Molecular Therapeutics Inc

4d Molecular Therapeutics Inc stock improved 10.47% today.


4D Molecular Therapeutics Inc operates with a business model focused on developing innovative gene therapy products to address serious genetic diseases. The company utilizes its proprietary technology platform to design and optimize viral vectors for targeted gene delivery. With a strong commitment to research and development, 4D Molecular Therapeutics collaborates with partners in academia, industry, and patient organizations to advance transformative treatments for patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 211.827 mill. $ 0.023 mill. $ -176.439 mill. 56 mill. - Y/Y -50.00 %
Market Cap. Revenues TTM Net Income TTM

$ 211.827 mill.
$ 0.023 mill.


$ -176.439 mill.
Employees Shares Outstanding P/E

95
56 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -50.00 %
MRQ Y/Y - %


IOVA

$1.83

$0.1700 10.24%
Today's


IOVA

$1.83

$0.1700 10.24%



Iovance Biotherapeutics inc

Iovance Biotherapeutics Inc stock improved 10.24% today.


Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient*s own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 590.848 mill. $ 212.679 mill. $ -375.364 mill. 323 mill. - Y/Y 6,798.46 %
Market Cap. Revenues TTM Net Income TTM

$ 590.848 mill.
$ 212.679 mill.


$ -375.364 mill.
Employees Shares Outstanding P/E

135
323 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 6,798.46 %
MRQ Y/Y - %


RGNX

$9.79

$0.9000 10.12%
Today's


RGNX

$9.79

$0.9000 10.12%



Regenxbio Inc

Regenxbio Inc shares increased 10.12% today.


Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 503.539 mill. $ 156.718 mill. $ -157.689 mill. 51 mill. - Y/Y 469.79 %
Market Cap. Revenues TTM Net Income TTM

$ 503.539 mill.
$ 156.718 mill.


$ -157.689 mill.
Employees Shares Outstanding P/E

353
51 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 469.79 %
MRQ Y/Y - %


AGEN

$3.79

$0.3100 8.91%
Today's


AGEN

$3.79

$0.3100 8.91%



Agenus Inc

Agenus Inc stock improved 8.91% today.


Agenus Inc is a biotechnology company that primarily focuses on the discovery and development of immune-based therapies for cancer treatment. Their business model revolves around leveraging their proprietary technologies and capabilities to develop and commercialize therapeutic antibodies and vaccines. Agenus Inc also collaborates with other pharmaceutical companies through licensing agreements and partnerships to further advance their product pipeline.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 92.738 mill. $ 99.524 mill. $ -195.187 mill. 24 mill. - Y/Y -14.07 %
Market Cap. Revenues TTM Net Income TTM

$ 92.738 mill.
$ 99.524 mill.


$ -195.187 mill.
Employees Shares Outstanding P/E

114
24 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -14.07 %
MRQ Y/Y - %


TNYA

$0.488

$0.0384 8.54%
Today's


TNYA

$0.488

$0.0384 8.54%



Tenaya Therapeutics Inc

Tenaya Therapeutics Inc shares increased 8.54% today.


Tenaya Therapeutics Inc*s business model is centered around developing novel treatments for heart disease using regenerative medicine approaches, focusing on advanced therapies that repair and restore the heart*s function. They aim to bring these innovative therapies to patients by leveraging their expertise in drug discovery and development, and by collaborating with strategic partners in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 41.398 mill. $ - mill. $ -111.129 mill. 85 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 41.398 mill.
$ - mill.


$ -111.129 mill.
Employees Shares Outstanding P/E

89
85 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


BDTX

$2.11

$0.1600 8.21%
Today's


BDTX

$2.11

$0.1600 8.21%



Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc stock increased 8.21% today.


Black Diamond Therapeutics Inc*s business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 121.690 mill. $ 70.000 mill. $ 5.091 mill. 58 mill. 25.41 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 121.690 mill.
$ 70.000 mill.


$ 5.091 mill.
Employees Shares Outstanding P/E

202
58 mill.
25.41
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


XTNT

$0.715

$0.0526 7.94%
Today's


XTNT

$0.715

$0.0526 7.94%



Xtant Medical Holdings Inc

Xtant Medical Holdings Inc shares went up 7.94% today.


Xtant Medical Holdings Inc operates as a medical technology company that focuses on the development, production, and distribution of regenerative medical products and devices. It primarily offers orthopedic and spinal surgical implants and instruments, providing solutions to surgeons and patients for enhancing healing and improving patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 98.009 mill. $ 117.216 mill. $ -16.449 mill. 137 mill. - Y/Y 14.95 %
Market Cap. Revenues TTM Net Income TTM

$ 98.009 mill.
$ 117.216 mill.


$ -16.449 mill.
Employees Shares Outstanding P/E

232
137 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 14.95 %
MRQ Y/Y - %


ITOS

$8.41

$0.6000 7.68%
Today's


ITOS

$8.41

$0.6000 7.68%



Iteos Therapeutics Inc

Iteos Therapeutics Inc shares increased 7.68% today.


Iteos Therapeutics Inc is a company that focuses on developing innovative immunotherapies to treat cancer by targeting the tumor microenvironment.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 363.660 mill. $ - mill. $ -130.811 mill. 43 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 363.660 mill.
$ - mill.


$ -130.811 mill.
Employees Shares Outstanding P/E

157
43 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


LCTX

$0.4974

$0.0344 7.43%
Today's


LCTX

$0.4974

$0.0344 7.43%



Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc shares went up 7.43% today.


Lineage Cell Therapeutics Inc is a biotechnology company primarily focused on developing and commercializing novel cell therapies for degenerative diseases. They leverage their proprietary cell-based technology to create therapeutic products that target specific conditions like spinal cord injuries, age-related macular degeneration, and osteoarthritis. The company aims to provide innovative and effective treatments by utilizing their expertise in cellular biology and therapeutic research.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 112.439 mill. $ 9.557 mill. $ -16.167 mill. 226 mill. - Y/Y 4.02 %
Market Cap. Revenues TTM Net Income TTM

$ 112.439 mill.
$ 9.557 mill.


$ -16.167 mill.
Employees Shares Outstanding P/E

201
226 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 4.02 %
MRQ Y/Y - %


TARA

$3.42

$0.2300 7.21%
Today's


TARA

$3.42

$0.2300 7.21%



Protara Therapeutics Inc

Protara Therapeutics Inc stock went up 7.21% today.


Protara Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address significant unmet medical needs. Their business model revolves around identifying and advancing potential drug candidates that target specific diseases or conditions, conducting extensive research and development to ensure safety and efficacy, and ultimately seeking regulatory approvals and entering the market to make these therapies accessible to patients worldwide. Protara leverages collaborations and partnerships within the healthcare industry to support their research efforts and drive business growth.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 70.285 mill. $ - mill. $ -44.596 mill. 21 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 70.285 mill.
$ - mill.


$ -44.596 mill.
Employees Shares Outstanding P/E

27
21 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ENZN

$0.0999

$0.0067 7.19%
Today's


ENZN

$0.0999

$0.0067 7.19%



Enzon Pharmaceuticals inc

Enzon Pharmaceuticals Inc shares went up 7.19% today.


Enzon Pharmaceuticals Inc. operates under a business model that focuses on the research, development, and commercialization of therapeutic drugs to address unmet medical needs. The company primarily employs a licensing strategy, partnering with other pharmaceutical companies to advance their drug candidates through clinical development and regulatory approval. By leveraging collaborations and out-licensing opportunities, Enzon aims to bring new therapies to market efficiently while maximizing shareholder value.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 7.414 mill. $ 1.723 mill. $ -0.066 mill. 74 mill. - Y/Y -23.18 %
Market Cap. Revenues TTM Net Income TTM

$ 7.414 mill.
$ 1.723 mill.


$ -0.066 mill.
Employees Shares Outstanding P/E

-
74 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -23.18 %
MRQ Y/Y - %


CADL

$5.7

$0.3500 6.54%
Today's


CADL

$5.7

$0.3500 6.54%



Candel Therapeutics Inc

Candel Therapeutics Inc stock improved 6.54% today.


Candel Therapeutics Inc*s business model is centered around developing and commercializing advanced biotherapeutics for the treatment of cancer. They aim to leverage their proprietary oncolytic viral immunotherapy technology to deliver targeted therapies that stimulate the patient*s immune system to attack and eliminate tumors. Through partnerships and collaborations, they seek to expand their reach and accelerate the development and delivery of innovative treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 312.165 mill. $ - mill. $ -39.577 mill. 55 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 312.165 mill.
$ - mill.


$ -39.577 mill.
Employees Shares Outstanding P/E

38
55 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


MRNA

$26.39

$1.5300 6.15%
Today's


MRNA

$26.39

$1.5300 6.15%



Moderna Inc

Moderna Inc shares improved 6.15% today.


Moderna Inc*s business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10,186.540 mill. $ 3,177.000 mill. $ -3,357.000 mill. 386 mill. - Y/Y -35.33 %
Market Cap. Revenues TTM Net Income TTM

$ 10,186.540 mill.
$ 3,177.000 mill.


$ -3,357.000 mill.
Employees Shares Outstanding P/E

5,600
386 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -35.33 %
MRQ Y/Y - %


LENZ

$28.45

$1.6400 6.12%
Today's


LENZ

$28.45

$1.6400 6.12%



Lenz Therapeutics Inc

Lenz Therapeutics Inc shares improved 6.12% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 783.118 mill. $ - mill. $ -47.740 mill. 28 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 783.118 mill.
$ - mill.


$ -47.740 mill.
Employees Shares Outstanding P/E

42
28 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


SGMO

$0.4985

$0.0285 6.06%
Today's


SGMO

$0.4985

$0.0285 6.06%



Sangamo Therapeutics Inc

Sangamo Therapeutics Inc stock increased 6.06% today.


Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients* lives.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 109.804 mill. $ 63.756 mill. $ -79.449 mill. 220 mill. - Y/Y 1,238.25 %
Market Cap. Revenues TTM Net Income TTM

$ 109.804 mill.
$ 63.756 mill.


$ -79.449 mill.
Employees Shares Outstanding P/E

282
220 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 1,238.25 %
MRQ Y/Y - %


KOD

$3.71

$0.2100 6.00%
Today's


KOD

$3.71

$0.2100 6.00%



Kodiak Sciences Inc

Kodiak Sciences Inc shares improved 6.00% today.


Kodiak Sciences Inc operates as a biopharmaceutical company that focuses on researching, developing, and commercializing innovative therapeutics to treat various retinal diseases. Their business model revolves around the discovery and development of novel drugs, while also conducting clinical trials and pursuing partnerships to bring these therapies to the market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 195.689 mill. $ - mill. $ -190.629 mill. 53 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 195.689 mill.
$ - mill.


$ -190.629 mill.
Employees Shares Outstanding P/E

74
53 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


BNTX

$97.8

$5.0300 5.42%
Today's


BNTX

$97.8

$5.0300 5.42%



Biontech Se

Biontech Se stock improved 5.42% today.


Biontech SE*s business model focuses on the development and commercialization of novel mRNA-based immunotherapies for various diseases, including cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 23,755.441 mill. $ 4,277.280 mill. $ 1,041.936 mill. 243 mill. 22.80 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 23,755.441 mill.
$ 4,277.280 mill.


$ 1,041.936 mill.
Employees Shares Outstanding P/E

3,500
243 mill.
22.80
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y -90.14 %


ELUT

$1.81

$0.0900 5.23%
Today's


ELUT

$1.81

$0.0900 5.23%



Elutia Inc

Elutia Inc shares improved 5.23% today.


Elutia Inc operates as a technology company that specializes in the design and manufacturing of high-performance air purification systems. Their business model focuses on developing innovative and sustainable solutions to improve indoor air quality for various industries such as healthcare, education, hospitality, and more. By incorporating advanced technology and providing reliable products, Elutia aims to create a healthier and safer environment for their customers while also driving revenue through the sale and maintenance of their air purification systems.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 77.673 mill. $ 23.321 mill. $ -39.888 mill. 43 mill. - Y/Y -6.61 %
Market Cap. Revenues TTM Net Income TTM

$ 77.673 mill.
$ 23.321 mill.


$ -39.888 mill.
Employees Shares Outstanding P/E

-
43 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -6.61 %
MRQ Y/Y - %


ATYR

$3.44

$0.1700 5.20%
Today's


ATYR

$3.44

$0.1700 5.20%



Atyr Pharma Inc

Atyr Pharma Inc stock went up 5.20% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 256.092 mill. $ - mill. $ -64.022 mill. 74 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 256.092 mill.
$ - mill.


$ -64.022 mill.
Employees Shares Outstanding P/E

44
74 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


CHRS

$0.8

$0.0390 5.12%
Today's


CHRS

$0.8

$0.0390 5.12%



Coherus Biosciences inc

Coherus Biosciences Inc stock went up 5.12% today.


Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 92.686 mill. $ 197.496 mill. $ -130.937 mill. 116 mill. - Y/Y -90.14 %
Market Cap. Revenues TTM Net Income TTM

$ 92.686 mill.
$ 197.496 mill.


$ -130.937 mill.
Employees Shares Outstanding P/E

926
116 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -90.14 %
MRQ Y/Y - %


CHRO

$1.05

$0.0500 5.00%
Today's


CHRO

$1.05

$0.0500 5.00%



Channel Therapeutics Corporation

Channel Therapeutics Corporation stock increased 5.00% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ - mill. $ -7.361 mill. - mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ - mill.
$ - mill.


$ -7.361 mill.
Employees Shares Outstanding P/E

-
- mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ADAP

$0.2913

$0.0134 4.82%
Today's


ADAP

$0.2913

$0.0134 4.82%



Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Plc stock improved 4.82% today.


Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 449.231 mill. $ 179.889 mill. $ -69.895 mill. 1,542 mill. - Y/Y 3.73 %
Market Cap. Revenues TTM Net Income TTM

$ 449.231 mill.
$ 179.889 mill.


$ -69.895 mill.
Employees Shares Outstanding P/E

246
1,542 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 3.73 %
MRQ Y/Y - %


SLDB

$2.9

$0.1300 4.69%
Today's


SLDB

$2.9

$0.1300 4.69%



Solid Biosciences Inc

Solid Biosciences Inc stock improved 4.69% today.


Solid Biosciences Inc is a biotechnology company focused on developing gene therapies for individuals with Duchenne muscular dystrophy (DMD).


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 192.390 mill. $ - mill. $ -139.676 mill. 66 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 192.390 mill.
$ - mill.


$ -139.676 mill.
Employees Shares Outstanding P/E

100
66 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ADVM

$2.21

$0.0950 4.49%
Today's


ADVM

$2.21

$0.0950 4.49%



Adverum Biotechnologies Inc

Adverum Biotechnologies Inc shares increased 4.49% today.


Adverum Biotechnologies Inc*s business model is focused on developing gene therapies using its proprietary platform to deliver therapeutics for eye diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 46.273 mill. $ - mill. $ -153.159 mill. 21 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 46.273 mill.
$ - mill.


$ -153.159 mill.
Employees Shares Outstanding P/E

121
21 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


REPL

$8.2

$0.3500 4.46%
Today's


REPL

$8.2

$0.3500 4.46%



Replimune Group Inc

Replimune Group Inc shares improved 4.46% today.


Replimune Group Inc has a business model centered around the development of oncolytic immunotherapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 684.691 mill. $ - mill. $ -228.242 mill. 84 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 684.691 mill.
$ - mill.


$ -228.242 mill.
Employees Shares Outstanding P/E

80
84 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


RLAY

$2.93

$0.1200 4.27%
Today's


RLAY

$2.93

$0.1200 4.27%



Relay Therapeutics Inc

Relay Therapeutics Inc shares went up 4.27% today.


Relay Therapeutics Inc is a biotechnology company focused on developing targeted therapies for diseases by leveraging insights from protein motion. Their business model involves utilizing computational simulations and algorithms to discover and design small molecule therapies that can effectively target specific proteins involved in various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 495.853 mill. $ 7.679 mill. $ -333.386 mill. 169 mill. - Y/Y -23.26 %
Market Cap. Revenues TTM Net Income TTM

$ 495.853 mill.
$ 7.679 mill.


$ -333.386 mill.
Employees Shares Outstanding P/E

261
169 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -23.26 %
MRQ Y/Y - %



 

Worst Performing Stocks From The Worst Performing (Legal Cannabis) Industry Today





MTEX

$9.01

$-1.5350 -14.56%
Today's


MTEX

$9.01

$-1.5350 -14.56%





Mannatech Incorporated shares dropped -14.56% today.


Mannatech Incorporated*s business model revolves around marketing and selling nutritional supplements and personal care products. The company primarily operates through a multi-level marketing (MLM) system, where independent associates are incentivized to recruit, sell products, and build their own network of distributors. Mannatech emphasizes the potential for financial success and personal development within the MLM structure.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 17.128 mill. $ 114.099 mill. $ -0.220 mill. 2 mill. - Y/Y -11.55 %
Market Cap. Revenues TTM Net Income TTM

$ 17.128 mill.
$ 114.099 mill.


$ -0.220 mill.
Employees Shares Outstanding P/E

189
2 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -11.55 %
MRQ Y/Y - %


SNYR

$2.113

$-0.2670 -11.22%
Today's


SNYR

$2.113

$-0.2670 -11.22%





Synergy Chc Corp shares declined -11.22% today.


Synergy Chc Corp operates on a direct-to-consumer business model, specializing in the development, distribution, and marketing of pharmaceutical and healthcare products. They deliver their products through various channels, including online platforms and retail stores. Their focus is on providing high-quality and affordable healthcare solutions to consumers worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 16.036 mill. $ 34.684 mill. $ -9.295 mill. 8 mill. - Y/Y 136.95 %
Market Cap. Revenues TTM Net Income TTM

$ 16.036 mill.
$ 34.684 mill.


$ -9.295 mill.
Employees Shares Outstanding P/E

-
8 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 136.95 %
MRQ Y/Y 351.03 %


RGC

$352.0158

$-40.9842 -10.43%
Today's


RGC

$352.0158

$-40.9842 -10.43%





Regencell Bioscience Holdings Limited stock declined -10.43% today.


Regencell Bioscience Holdings Limited operates under a business model that focuses on the development and commercialization of advanced biotechnology products. The company employs research and development to create innovative solutions in the field of cell therapy, regenerative medicine, and related technologies. Through strategic partnerships and collaborations, Regencell aims to bring its products to market to address various medical conditions and contribute to the growth of the biotech industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4,580.734 mill. $ - mill. $ -6.062 mill. 13 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4,580.734 mill.
$ - mill.


$ -6.062 mill.
Employees Shares Outstanding P/E

11
13 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


TLRY

$0.4531

$-0.0419 -8.46%
Today's


TLRY

$0.4531

$-0.0419 -8.46%





Tilray Brands Inc stock dropped -8.46% today.


Tilray Brands Inc operates as a cannabis-focused consumer packaged goods company. They develop and market a range of cannabis products, including dried flower, oils, capsules, and beverages, catering to medical and recreational users. With a focus on innovation and brand-building, Tilray Brands Inc aims to establish a strong presence in the cannabis industry and deliver high-quality products to its customers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 411.570 mill. $ 826.287 mill. $ -928.836 mill. 908 mill. - Y/Y -1.27 %
Market Cap. Revenues TTM Net Income TTM

$ 411.570 mill.
$ 826.287 mill.


$ -928.836 mill.
Employees Shares Outstanding P/E

2,650
908 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -1.27 %
MRQ Y/Y - %


IMCC

$1.5441

$-0.1159 -6.98%
Today's


IMCC

$1.5441

$-0.1159 -6.98%





Im Cannabis Corp shares dropped -6.98% today.


Im Cannabis Corp operates as a vertically integrated cannabis company. They cultivate, manufacture, distribute, and sell medical cannabis and related products in Germany and Israel. Their business model focuses on combining production, distribution, and patient care to provide high-quality medical cannabis products to the growing market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 19.819 mill. $ 37.384 mill. $ -7.835 mill. 13 mill. - Y/Y -10.18 %
Market Cap. Revenues TTM Net Income TTM

$ 19.819 mill.
$ 37.384 mill.


$ -7.835 mill.
Employees Shares Outstanding P/E

100
13 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -10.18 %
MRQ Y/Y - %


UPXI

$9.64

$-0.5500 -5.40%
Today's


UPXI

$9.64

$-0.5500 -5.40%





Upexi Inc shares went down -5.40% today.


Upexi Inc is a technology-driven company that operates on a platform-based business model. They provide a wide range of services through their platform, connecting customers with various service providers. Their revenue is generated through commissions or transaction fees earned from the services provided on their platform.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 12.883 mill. $ 25.967 mill. $ -10.877 mill. 1 mill. - Y/Y -85.52 %
Market Cap. Revenues TTM Net Income TTM

$ 12.883 mill.
$ 25.967 mill.


$ -10.877 mill.
Employees Shares Outstanding P/E

82
1 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -85.52 %
MRQ Y/Y - %


CHUC

$0.085

$-0.0040 -4.49%
Today's


CHUC

$0.085

$-0.0040 -4.49%





Charlie S Holdings Inc shares went down -4.49% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 20.618 mill. $ 6.718 mill. $ -3.034 mill. 243 mill. - Y/Y -39.99 %
Market Cap. Revenues TTM Net Income TTM

$ 20.618 mill.
$ 6.718 mill.


$ -3.034 mill.
Employees Shares Outstanding P/E

-
243 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -39.99 %
MRQ Y/Y - %


SNDL

$1.3

$-0.0500 -3.70%
Today's


SNDL

$1.3

$-0.0500 -3.70%





Sndl Inc shares declined -3.70% today.


Sndl Inc operates as a cannabis dispensary and retailer. The company sources and curates a wide variety of cannabis products and accessories for its customers. They generate revenue by selling these products through their physical stores and online channels.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 326.213 mill. $ 696.299 mill. $ -135.238 mill. 251 mill. - Y/Y 27.63 %
Market Cap. Revenues TTM Net Income TTM

$ 326.213 mill.
$ 696.299 mill.


$ -135.238 mill.
Employees Shares Outstanding P/E

-
251 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 27.63 %
MRQ Y/Y - %


CRON

$2.07

$-0.0700 -3.27%
Today's


CRON

$2.07

$-0.0700 -3.27%





Cronos Group Inc stock went down -3.27% today.


Cronos Group Inc operates as a vertically integrated cannabis company. Their business model revolves around cultivating, manufacturing, and distributing medical and recreational cannabis products. They aim to capture market share through their unique brands and partnerships with influential companies in various sectors.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 773.051 mill. $ 117.615 mill. $ 40.022 mill. 373 mill. - Y/Y 65.68 %
Market Cap. Revenues TTM Net Income TTM

$ 773.051 mill.
$ 117.615 mill.


$ 40.022 mill.
Employees Shares Outstanding P/E

431
373 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 65.68 %
MRQ Y/Y - %


ACB

$5.02

$-0.1100 -2.14%
Today's


ACB

$5.02

$-0.1100 -2.14%





Aurora Cannabis Inc shares declined -2.14% today.


Aurora Cannabis Inc operates as a vertically integrated cannabis company, controlling every aspect of the supply chain from cultivation to distribution. They focus on producing and selling medical and recreational cannabis products globally. This business model allows them to have greater control over product quality, streamline operations, and capitalize on the growing market for cannabis.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 228.958 mill. $ 354.619 mill. $ -53.104 mill. 46 mill. - Y/Y 109.16 %
Market Cap. Revenues TTM Net Income TTM

$ 228.958 mill.
$ 354.619 mill.


$ -53.104 mill.
Employees Shares Outstanding P/E

1,000
46 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 109.16 %
MRQ Y/Y - %


CGC

$1.64

$-0.0200 -1.20%
Today's


CGC

$1.64

$-0.0200 -1.20%





Canopy Growth Corporation shares dropped -1.20% today.


Canopy Growth Corporation*s business model revolves around being a leading producer and distributor of cannabis products, including both medicinal and recreational cannabis. The company focuses on cultivating, processing, and manufacturing various cannabis-based products, such as dried flowers, oils, and edibles. Canopy Growth Corporation also aims to expand its market presence through strategic partnerships and acquisitions, both domestically and internationally.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 180.903 mill. $ 102.671 mill. $ -359.763 mill. 110 mill. - Y/Y -10.67 %
Market Cap. Revenues TTM Net Income TTM

$ 180.903 mill.
$ 102.671 mill.


$ -359.763 mill.
Employees Shares Outstanding P/E

2,500
110 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -10.67 %
MRQ Y/Y - %


BTMD

$4.06

$-0.0400 -0.98%
Today's


BTMD

$4.06

$-0.0400 -0.98%





Biote Corp shares dropped -0.98% today.


Biote Corp*s business model focuses on the development and commercialization of biotechnology products or services.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 142.416 mill. $ 198.051 mill. $ 33.554 mill. 35 mill. 19.44 Y/Y 28.30 %
Market Cap. Revenues TTM Net Income TTM

$ 142.416 mill.
$ 198.051 mill.


$ 33.554 mill.
Employees Shares Outstanding P/E

1,000
35 mill.
19.44
Revenue Growth Income Growth

MRQ Y/Y 28.30 %
MRQ Y/Y - %


USNA

$30.07

$-0.2000 -0.66%
Today's


USNA

$30.07

$-0.2000 -0.66%





Usana Health Sciences Inc shares went down -0.66% today.


Usana Health Sciences Inc is a multi-level marketing company that primarily sells nutritional supplements and personal care products. Through a network of independent distributors, the company focuses on direct selling and recruitment to generate sales and expand its customer base.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 573.886 mill. $ 875.654 mill. $ 34.813 mill. 19 mill. 16.49 Y/Y 9.38 %
Market Cap. Revenues TTM Net Income TTM

$ 573.886 mill.
$ 875.654 mill.


$ 34.813 mill.
Employees Shares Outstanding P/E

1,700
19 mill.
16.49
Revenue Growth Income Growth

MRQ Y/Y 9.38 %
MRQ Y/Y -43.82 %


NAGE

$10.93

$-0.0200 -0.18%
Today's


NAGE

$10.93

$-0.0200 -0.18%





Niagen Bioscience Inc stock went down -0.18% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 909.726 mill. $ 107.925 mill. $ 14.105 mill. 83 mill. 67.12 Y/Y 37.59 %
Market Cap. Revenues TTM Net Income TTM

$ 909.726 mill.
$ 107.925 mill.


$ 14.105 mill.
Employees Shares Outstanding P/E

142
83 mill.
67.12
Revenue Growth Income Growth

MRQ Y/Y 37.59 %
MRQ Y/Y - %


AMMJ

$0.0013

$0.0000 0.00%
Today's


AMMJ

$0.0013

$0.0000 0.00%





American Cannabis Company Inc shares dropped 0.00% today.


American Cannabis Company Inc is a cannabis consulting and solutions provider operating in the United States. They offer a range of services including cultivation facility design, equipment sourcing, branding, and operational support to help businesses in the cannabis industry succeed. Their business model revolves around providing expertise and resources to clients in order to help them navigate the complexities of the cannabis market and maximize their profitability.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.242 mill. $ 1.599 mill. $ -0.769 mill. 186 mill. 1.51 Y/Y -49.35 %
Market Cap. Revenues TTM Net Income TTM

$ 0.242 mill.
$ 1.599 mill.


$ -0.769 mill.
Employees Shares Outstanding P/E

-
186 mill.
1.51
Revenue Growth Income Growth

MRQ Y/Y -49.35 %
MRQ Y/Y - %


NTRR

$0.0002

$0.0000 0.00%
Today's


NTRR

$0.0002

$0.0000 0.00%





Neutra Corp shares went down 0.00% today.


Neutra Corp is a company that focuses on the development and distribution of natural health products and supplements. Their business model centers around researching, producing, and marketing these products to cater to the growing demand for natural health and wellness solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.584 mill. $ 5.930 mill. $ -0.470 mill. 2,918 mill. - Y/Y -94.39 %
Market Cap. Revenues TTM Net Income TTM

$ 0.584 mill.
$ 5.930 mill.


$ -0.470 mill.
Employees Shares Outstanding P/E

-
2,918 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -94.39 %
MRQ Y/Y - %


MDWD

$20.51

$0.0300 0.15%
Today's


MDWD

$20.51

$0.0300 0.15%





Mediwound Ltd shares improved 0.15% today.


Mediwound Ltd operates through the development, manufacturing, and commercialization of biopharmaceutical products. Their business model primarily involves leveraging their expertise in biotechnology to create innovative therapies for the treatment of severe burns, chronic wounds, and other healing disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ - mill. $ 0.000 mill. - mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ - mill.
$ - mill.


$ 0.000 mill.
Employees Shares Outstanding P/E

89
- mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


CYAN

$0.321

$0.0009 0.28%
Today's


CYAN

$0.321

$0.0009 0.28%





Cyanotech Corp stock improved 0.28% today.


Cyanotech Corp operates as a biotechnology company that specializes in the production of natural products derived from microalgae. The company cultivates and harvests microalgae, primarily spirulina and astaxanthin, which are used in various industries including dietary supplements, food and beverage, and cosmetics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.297 mill. $ 23.810 mill. $ -4.657 mill. 7 mill. - Y/Y 11.40 %
Market Cap. Revenues TTM Net Income TTM

$ 2.297 mill.
$ 23.810 mill.


$ -4.657 mill.
Employees Shares Outstanding P/E

62
7 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 11.40 %
MRQ Y/Y - %


FTLF

$13.79

$0.1500 1.10%
Today's


FTLF

$13.79

$0.1500 1.10%





Fitlife Brands Inc shares improved 1.10% today.


Fitlife Brands Inc is a health and wellness company that operates through a business model focused on the development, marketing, and distribution of nutrition supplements and other related products. They create and promote their own branded supplements, as well as distribute products from other reputable brands. Their aim is to provide customers with high-quality and innovative products to support their fitness and well-being goals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 136.880 mill. $ 63.667 mill. $ 8.842 mill. 10 mill. 19.10 Y/Y -2.54 %
Market Cap. Revenues TTM Net Income TTM

$ 136.880 mill.
$ 63.667 mill.


$ 8.842 mill.
Employees Shares Outstanding P/E

-
10 mill.
19.10
Revenue Growth Income Growth

MRQ Y/Y -2.54 %
MRQ Y/Y -6.57 %


NAII

$3.31

$0.0600 1.85%
Today's


NAII

$3.31

$0.0600 1.85%





Natural Alternatives International Inc stock went up 1.85% today.


Natural Alternatives International Inc is a company that operates in the health and wellness industry. They specialize in developing and manufacturing science-based nutritional supplements and providing contract manufacturing services to clients across the globe.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 19.597 mill. $ 121.269 mill. $ -7.625 mill. 6 mill. - Y/Y 38.06 %
Market Cap. Revenues TTM Net Income TTM

$ 19.597 mill.
$ 121.269 mill.


$ -7.625 mill.
Employees Shares Outstanding P/E

227
6 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 38.06 %
MRQ Y/Y - %


AKAN

$1.225

$0.0250 2.08%
Today's


AKAN

$1.225

$0.0250 2.08%





Akanda Corp shares increased 2.08% today.


Akanda Corp is a technology company that employs a software-centric approach to network infrastructure for enterprises. Their business model focuses on providing open-source software solutions intended to simplify network operations and enhance network agility. By leveraging container-based virtualization technologies, they enable organizations to efficiently deploy and manage networks, ultimately optimizing performance and reducing costs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.519 mill. $ 2.160 mill. $ -32.275 mill. 5 mill. - Y/Y -17.55 %
Market Cap. Revenues TTM Net Income TTM

$ 5.519 mill.
$ 2.160 mill.


$ -32.275 mill.
Employees Shares Outstanding P/E

-
5 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -17.55 %
MRQ Y/Y - %


MNMD

$7.01

$0.4100 6.21%
Today's


MNMD

$7.01

$0.4100 6.21%





Mind Medicine Mindmed Inc shares went up 6.21% today.


Mind Medicine (MindMed) is a biotech company that focuses on the development of psychedelic medicines to address mental health disorders. Their business model revolves around conducting clinical trials, obtaining regulatory approvals, and commercializing their psychedelic-based therapies. By leveraging scientific research and strategic partnerships, MindMed aims to provide innovative solutions for mental illness treatment and disrupt the traditional pharmaceutical industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 610.511 mill. $ - mill. $ -77.627 mill. 87 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 610.511 mill.
$ - mill.


$ -77.627 mill.
Employees Shares Outstanding P/E

28
87 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


FFNTF

$0.0029

$0.0005 20.83%
Today's


FFNTF

$0.0029

$0.0005 20.83%





4front Ventures Corp stock increased 20.83% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.650 mill. $ 67.991 mill. $ -36.403 mill. 914 mill. - Y/Y -25.52 %
Market Cap. Revenues TTM Net Income TTM

$ 2.650 mill.
$ 67.991 mill.


$ -36.403 mill.
Employees Shares Outstanding P/E

300
914 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -25.52 %
MRQ Y/Y - %


BON

$1.3

$1.2362 1,937.62%
Today's


BON

$1.3

$1.2362 1,937.62%





Bon Natural Life Limited stock increased 1,937.62% today.


Bon Natural Life Limited operates as a direct selling company that offers a range of natural and wellness products. They adopt a business model where independent distributors sell their products directly to customers, earning a commission from their sales.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.124 mill. $ 23.110 mill. $ 0.345 mill. 2 mill. 7.65 Y/Y -19.87 %
Market Cap. Revenues TTM Net Income TTM

$ 3.124 mill.
$ 23.110 mill.


$ 0.345 mill.
Employees Shares Outstanding P/E

150
2 mill.
7.65
Revenue Growth Income Growth

MRQ Y/Y -19.87 %
MRQ Y/Y -92.42 %



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com